Posted by Michael Wonder on 26 Oct 2017
Tesaro announces U.S. FDA approval of Varubi IV for delayed nausea and vomiting associated with cancer chemotherapy
25 October 2017 - Availability of new formulation offers healthcare providers the flexibility to choose oral or IV administration.
Tesaro today announced that the U.S. FDA has approved VARUBI® (rolapitant) IV in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. Delayed nausea and vomiting can occur anytime between 25 and 120 hours following chemotherapy, and is often extremely debilitating.
